ArticleBMC cancer2018

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.

Ana Fernández et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.